摩洛哥弥漫浸润性胶质瘤的临床病理特征与预后因素:基于2021 WHO分类的单中心回顾性研究
胶质母细胞瘤占75%,中位年龄56岁,男女比2:1;64例胶质母细胞瘤患者中位总生存期9个月,2年生存率27%,多模式治疗是唯一独立预后因素。
要点
- 胶质母细胞瘤占75%,好发于顶叶(31%)、额叶(26%)和颞叶(21%)。
- 胶质母细胞瘤患者中位OS为9个月,2年生存率为27%。
- 年轻年龄和多模式治疗与更好结局相关,治疗是唯一独立预后因素。
核心结论
- 该机构胶质瘤临床病理特征与国际系列一致,但总生存期较低。
- 接受完整多模式治疗的患者生存特征与已发表国际数据相当,治疗是本机构结局的决定因素。
研究设计与样本
- 摩洛哥卡萨布兰卡Mohammed VI癌症中心的回顾性描述性单中心研究。
- 对64例胶质母细胞瘤患者采用Kaplan-Meier法、log-rank检验和Cox回归模型评估总生存期。
主要发现
- 122例患者中位年龄56岁,男女比例为2:1。
- 胶质母细胞瘤为主要亚型(75%),主要位于顶叶(31%)、额叶(26%)和颞叶(21%)。
- 常见症状为运动障碍、头痛和癫痫发作。
- 胶质母细胞瘤患者中位OS为9个月,2年生存率为27%。
- 年轻年龄和多模式治疗与更好结局相关,治疗是唯一独立预后因素。
关键数值与推荐
- 胶质母细胞瘤患者中位OS为9个月,2年生存率为27%。
- 胶质母细胞瘤占全部弥漫浸润性胶质瘤的75%。
- 发病部位以顶叶(31%)、额叶(26%)、颞叶(21%)为主。
临床怎么用
- 应重视多模式治疗在胶质母细胞瘤管理中的核心作用。
- 可考虑扩大分子检测和结构化临床随访以优化生存结局。
局限性
- 单中心回顾性描述性研究,样本量有限。
- 总生存分析仅纳入64例胶质母细胞瘤患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gliomas are the most common primary malignant tumors of the central nervous system. Their incidence and survival vary across low/middle and high-income countries. This study summarizes the epidemiological, clinical, and therapeutic features of a Moroccan cohort, based on the WHO 2021 classification. METHODS: We conducted a retrospective descriptive single-center study at the Mohammed VI Cancer Center in Casablanca, including 122 patients with diffuse infiltrating gliomas diagnosed between January 2019 and November 2024. Demographic, clinical, and therapeutic data were analyzed. Overall survival was assessed in 64 glioblastoma patients using Kaplan-Meier methods, log-rank tests, and Cox regression models. RESULTS: Among 122 patients, the median age was 56 years with a 2:1 male to female ratio. Glioblastoma was the predominant subtype (75%), localized predominantly in the parietal (31%), frontal (26%), and temporal (21%) lobes. The frequently observed symptoms were motor deficits, headaches, and seizures. For glioblastoma patients, the median OS was 9 months, with a 2-year survival rate of 27%. Younger age and multimodal treatment were associated with better outcomes, with treatment emerging as the only independent prognostic factor. CONCLUSIONS: Our institutional clinicopathological features align with international series, whereas overall survival stands lower. Patients receiving full multimodal therapy achieved survival profiles comparable to published international data, identifying treatment as a determinant of outcome in our setting. Expanded molecular testing and structured clinical follow-up represent potential strategies to optimize survival outcomes within our institutional context.
引用
- Bouchra O, El Baha C, El Guendouzi S, et al. Clinicopathological Characteristics and Prognostic Factors of Diffuse Infiltrating Glioma in Morocco: A Retrospective Single-Center Institutional Experience Under the 2021 WHO Classification. World Neurosurg. 2026. PMID: 42542166. doi:10.1016/j.wneu.2026.125217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。